Small Randomized Clinical Trial In Turkey: Results Reveals Ivermectin-Added to Local Reference Treatment Reduced Mortality Rate in Severe COVID Cases

Small Randomized Clinical Trial In Turkey Results Reveals Ivermectin-Added to Local Reference Treatment Reduced Mortality Rate in Severe COVID Cases

Yet another clinical trial result points out the possible benefits of ivermectin in relations to COVID-19 treatments.  This time, a study led by researchers from Afyonkarahisar Health Sciences University, as well as other academic medical centers in Turkey, used a combination of treatments to determine if ivermectin would have an impact. Both the study group and the control group received a combination of hydroxychloroquine, favipiravir, and azithromycin. TrialSite notes that these drugs are commonly used in Turkey against the coronavirus. So this small study added Ivermectin to determine greater efficacy. The study results were recently published in the peer review journal BMC Infectious Diseases. This randomized, controlled, single-blind Phase 3 study focused on patients infected with severe COVID-19 pneumonia. The study team found that ivermectin can boost clinical recovery improvement in prognostic laboratory parameters while decreasing mortality rates even in severe cases. The investigators led by corresponding author Nurullah Okumus suggest that ivermectin should be considered as a therapy for COVID-19 treatment regimens or as an additional...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee